Use of autologous blood as part of the perfusate for cardiopulmonary bypass: a priming technique

Abstract

In an attempt to replace the oncotic and protein coating capabilities of serum albumin in the perfusate, we established a priming protocol that used autologous blood as part of the perfusate solution. Prior to March 1, 1999, our standard priming protocol was 1650 ml of crystalloid with 250 ml of 5% serum albumin and 5000 units of heparin. After removing albumin from our prime, our standard protocol was altered to include 40 ml of the patient’s autologous blood in 1800 ml of crystalloid and 10000 units of heparin. To determine the intraoperative effects of using albumin/crystalloid primes (Group A), autologous blood/crystalloid primes (Group B) and crystalloid primes (Group C), a total of 178 patients were sequentially evaluated. Intraoperative parameters evaluated were total protein (TP), colloid osmotic pressure (COP), platelets (Plts) and fluid requirements during cardiopulmonary bypass (CPB). During an overlapping 12-month period of time, 1092 consecutive cardiac surgical cases using CPB (584 albumin prime; 508 autologous blood prime) were evaluated for clinical outcomes in terms of mortality and length of hospitalization. In addition, over a period of 15 months, 1458 patients in both the autologous blood/crystalloid group and the crystalloid only group were evaluated for the incidence of high-pressure excursions (HPE) after going on bypass. Comparative reviews of TP, COP and Plts demonstrated no significant difference 10 min after the start of bypass between Groups A and B. However, in Group C, there was a statistically significant increase in the intraoperative fluid requirements during CPB, compared to both of the other groups. There was no significant difference in the incidence of HPE, with an occurrence of 1.04% in the crystalloid only group and 1.11% in the autologous blood/crystalloid group. Autologous blood perfusates were identical to albumin perfusates in their platelet protection and reduction of fluid shifts during the intraoperative period.

Get full access to this article

View all access options for this article.

References

Gurjar Y , Bowman J. Prevention of platelet adhesion to extracorporeal surfaces . J Extra-Corpor Technol 1984; 16: 104-107 .

Amiji M , Park H , Park K. Study on the prevention of surface induced platelet activation by albumin coating . J Biomater Sci, Polym Ed 1992; 3: 375-388 .

Saltzman E , Merrill E , Binder A et al. Protein -platelet interaction on heparinized surfaces . J Biomed Mater Res 1969; 3: 69-81 .

Ryu G , Han D , Kim Y et al. Albumin immobilized polyurethane and its blood compatibility . ASAIO 1992; 38: M644-M648 .

Beshere G , Camerlengo L , Dearing J. Estimation of colloid osmotic pressure during hemodilutional cardiopulmo-nary bypass . J Extra-Corpor Technol 1982; 14: 381-384 .

Blackwell M , Riley J , McCall M et al. An evaluation of three methods for determining colloid osmotic pressure . J Extra-Corpor Technol 1994; 26: 18-22 .

Rabelo R , Oliveira S , Tanaka H et al. The influence of the nature of the prime on postperfusion pulmonary changes . J Thorac Cardiovasc Surg 1973; 66: 782-793 .

Laks H , Standeven J , Blair O et al. The effects of cardiopulmonary bypass with crystalloid and colloid hemo-dilution on myocardial extravascular water . J Thorac Cardiovasc Surg 1997; 73: 129-138 .

Holman R , Khan A , Belay E et al. Creutzfeldt-Jakob disease in the United States, 1979 - 1984: using national mortality data to assess the possible occurrence of variant cases . Emerging Infect Dis 1996; 2: 333-337 .

10.

Myers G. A comparative review of crystalloid, albumin, Pentastarch and Hetastarch as perfusates for cardiopulmonary bypass . J Extra-Corpor Technol 1997; 29: 30-35 .

11.

Hett D , Smith D. A survey of priming solutions used for cardiopulmonary bypass . Perfusion 1994; 9: 19-22 .

12.

Himpe D , VanCauwelaert P , Neels H et al. Priming solutions for cardiopulmonary bypass: comparison of three colloids . J Cardiothoracic Vasc Anaesth 1991; Oct: 457-466 .

13.

Bonser R , Dave J , Davies E et al. Reduction of compliment activation during bypass by prime manipulation . Ann Thorac Surg 1990; Feb 49: 279-283 .

14.

Schaadt J. Oxygenator thrombosis: an international phenomenon . Perfusion 1999; 14: 425-435 .

15.

Myers G. An update on perfusate compositions . Presented at Mechanisms of Perfusion XIII, May 1998. Orlando, Florida.

16.

Palanzo D , Zarro D , Montesano R et al.

Albumin in the cardiopulmonary bypass prime: how little is enough?

Perfusion 1999; May 14: 167-172 .

17.

London M , Frank M , Verrier E et al. The safety and efficacy of 10% Pentastarch as a cardiopulmonary bypass priming solution . J Thorac Cardiovasc Surg 1992; 104: 284-296 .

18.

Sade R , Stroud M , Crawford F et al. A prospective randomized study of hydroxyethyl starch, albumin and lactated ringers solution as a priming fluid for CPB . J Thorac Cardiovasc Surg 1985; 89: 713-722 .

19.

Blomback M , Kronlund P , Aberg B et al. Pathological fibrin formation and cold induced clotting of membrane oxygenators during cardiopulmonary bypass . J Cardiothoracic Vasc Anaesth 1995; 9: 34-43 .

20.

Wahba A , Philipp A , Behr R et al. Heparin coated equipment reduces the risk of oxygenator failure . Ann Thorac Surg 1998; 86: 668-669 .

21.

Cope J , Banks D , Mareney M et al. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations . Ann Thorac Surg 1997; 63: 78-82 .

22.

Vree TB , Shimoda M , Driessen JJ et al. Decreased plasma albumin concentration results in increased volume distribution and decreased elimination of midazolam in intensive care patients . Clin Pharmacol Ther 1989; 46: 537-544 .

23.

Ikenoue N , Saitsu Y , Shimoda M et al. Disease induced alterations in plasma drug binding proteins and the influence on drug binding percentages in dogs . Vet Q 2000; 22: 43-49 .

24.

Frostell-Karlson A , Remaeus A , Roos H et al. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels . J Med Chem 2000; 43: 1986-1992 .

25.

Hammaren E , Rosenberg P , Hynenem M. Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro . Br J Anaesth 1999; 82: 38-40 .

26.

Mazoit J , Samii S. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics . Br J Clin Pharmacol 1999; 47: 35-42 .

27.

Altmayer P , Buch U , Buch H. Propofol binding to human blood proteins . Arzneim.-Forsch 1995; 45: 1053-1056 .

28.

Nader-Djalal N , Khadra W , Spaulding W et al. Does propofol alter gas exchange in membrane oxygenators . Ann Thorac Surg 1998; 66: 298-299 .